| Date | Title | Description |
| 05.06.2026 | China's Leading Innovative Drug Developer for Allergic and Autoimmune Diseases LongBio Pharma Lists on Hong Kong Stock Exchange | SHANGHAI, June 5, 2026 /PRNewswire/ -- LongBio Pharma, a portfolio company of Qiming Venture Partners and a leading innovative drug developer for allergic and autoimmune diseases in China, listed on the Hong Kong Stock Exchange on June 5, 2... |
| 27.05.2026 | Domestic Display Chip Leader Viewtrix Technology Listed on Hong Kong Stock Exchange | SHANGHAI, May 27, 2026 /PRNewswire/ -- Viewtrix Technology, a portfolio company of Qiming Venture Partners and a leading display chip design enterprise in China, successfully listed on the Hong Kong Stock Exchange, marking the sixth IPO for... |
| 30.11.2025 | Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Aid Fund for Post-Fire Recovery | SHANGHAI, Nov. 30, 2025 /PRNewswire/ -- On the afternoon of November 26, a major Grade 5 fire spread across multiple residential buildings in Wang Fuk Court in Tai Po, Hong Kong, causing severe casualties and drawing widespread public conce... |
| 16.10.2025 | Qiming Venture Partners' Portfolio Company Yunji Technology Successfully Lists on the Hong Kong Stock Exchange | SHANGHAI, Oct. 16, 2025 /PRNewswire/ -- Yunji Technology, a global leader in the hospitality robotic-based AI agents market and a portfolio company of Qiming Venture Partners, has successfully debuted on the Hong Kong Stock Exchange on Octo... |
| 24.03.2025 | China’s biotech sector is undervalued given its AI-driven opportunities: Investor | - |
| 02.06.2024 | WHO members approve steps to bolster health regulations for pandemics | - |
| 25.05.2024 | Efforts to draft pandemic treaty falter as countries disagree on steps | - |
| 29.04.2024 | China's top Covid-19 vaccine scientist expelled from Parliament for graft | - |
| 09.01.2023 | COVID-19 vaccines: From nasal drops to a redesign, what 2023 could have in store | Several vaccine companies say they are expecting breakthroughs as early as this year as they pursue new ways to protect people against SARS-CoV-2, the virus that causes COVID-19.
The Food and Drug Administration is set to convene a panel of... |
| 06.09.2022 | Covid-19 roundup: CanSino’s inhaled vaccine gets thumbs-up from Chinese regulators; Sinovac gets go-ahead for booster trial in Chile | While the world has been focused on injectable booster shots to address the Omicron variant, one company focused on a different approach has seen its product take a major step forward.
Chinese biotech CanSino Biologics h... |
| 19.05.2022 | CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing | TIANJIN, China, May 19, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that the World Health Organization ("WHO") has granted Emergency Use Listing ("EUL")... |
| 25.04.2022 | CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research | TIANJIN, China, April 25, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: , HKEX: 06185) today announced its new brand identity, which is intended to represent the Company's continuous d... |
| 04.04.2022 | CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China | TIANJIN, April 4, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of China ("NMPA") grant... |
| 22.03.2022 | CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia | TIANJIN, China, March 22, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade... |
| 14.03.2022 | Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant | TIANJIN, China, March 14, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that medRxiv, a preprint platform for preliminary biomedical research, published an academic paper1 on... |
| 21.02.2022 | CanSinoBIO's Convidecia™ Approved as Heterologous Booster in China | TIANJIN, China, Feb. 21, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: ... |
| 17.01.2022 | Covid: la tecnologia dell’irlandese Aerogen per il 1° vaccino spray al mondo | Un vaccino anti Covid via aerosol? Non è fantascienza, ma realtà grazie all’irlandese Aerogen, leader mondiale nella somministrazione di farmaci aerosol ad alte prestazioni.
Aerogen ha annunciato la partnership con la cinese CanSino Biotec... |
| 12.01.2022 | CanSino Biologics : Could CanSino's inhaled coronavirus vaccine booster be a quick, needle-free option? | Could CanSino's inhaled coronavirus vaccine booster be a quick, needle-free option?
2022-01
Study finds Chinese vaccine induces a higher level of immune response than a Sinovac booster for those vaccinated with two Sinovac shots
Inhaled vac... |
| 11.01.2022 | Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster | TIANJIN, China, Jan. 11, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that Preprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lanc... |
| 09.01.2022 | CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China | TIANJIN, China, Jan. 9, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration of China ("NMPA") granted approval for its ACYW135... |
| 24.06.2021 | CanSino Biologics : CanSinoBIO Announces Approval for Its Group A and Group C Meningococcal Conjugate Vaccine in China | CanSinoBIO Announces Approval for Its Group A and Group C Meningococcal Conjugate Vaccine in China
2021-06
Tianjin, June 23, 2021CanSino Biologics Inc. ('CanSinoBIO') (SHSE: 688185, HKEX: 06185) today announced that the National Medical Pro... |
| 24.05.2021 | CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™ | A major step for introducing Convidecia™ to more countries and people in need for protection
Vaccine has been approved in China, Mexico, Pakistan, Hungary and Chile
Provides timely clinical protection for adults aged 18 and above, including... |
| 22.05.2021 | CANSINO BIOLOGICS INC.
CanSino Biologics : CanSinoBIO Receives EU GMP Certificate | CanSinoBIO Receives EU GMP Certificate
2021-05
Tianjin, May 21, 2021
CanSino Biologics Inc. ('CanSinoBIO') (SHSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector) ('Ad5-nCoV', t... |
| 26.03.2021 | CANSINO BIOLOGICS INC.
CanSino Biologics : ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 CLOSURE OF REGISTER OF MEMBERS | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 26.03.2021 | CanSino Biologics : ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 CLOSURE OF REGISTER OF MEMBERS | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| 16.04.2020 | Covid-19 vaccine tracker updated to include GSK/Sanofi collaboration | By Jeff Craven
Currently, there are no FDA-approved therapies or vaccines for SARS-CoV-2, the virus that causes Covid-19. The National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes... |
| 09.04.2020 | Covid-19 Tracker updates vaccine candidates | By Jeff Craven
On March 11, the World Health Organization classified the Covid-19 outbreak as a pandemic. The disease has reached nearly every country, infecting hundreds of thousands of people and killing thousands.
Curr... |
| 19.03.2020 | An updated guide to the coronavirus drugs and vaccines in development | In the months since the novel coronavirus rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic.
Some are taking a cue from older antivirals. Some are... |
| 29.01.2016 | China’s Qiming Venture Partners closing $650M fund, reaches $600M in healthcare investments | The company says it has invested more than $600 million in the healthcare sector in the past seven years. In 2014, it invested in a dozen healthcare startups, offering an average of $10 million to each, it said in a statement.
“Qiming curre... |
| - | China’s Qiming Venture Partners closing $650M fund, reaches $600M in healthcare investments | China-based investment firm Qiming Venture Partners has been raising a $650 million fund – its fifth – according to an SEC filing. While the fund focuses on China-based startups in the information technology, healthcare and clean tech space... |
